N-Acetyl Selank Amidate
N-Acetyl Selank Amidate | Enhanced Anxiolytic Nootropic
DoseGear research brief
NA-Selank Amidate is an enhanced version of Selank, the anxiolytic nootropic peptide developed at Russia's Institute of Molecular Genetics. The N-acetyl group improves blood-brain barrier penetration and creates more stable metabolites, while the C-terminal amidation further enhances metabolic stability and receptor binding. Unlike benzodiazepines, it provides anxiety relief without sedation, dependency, or cognitive impairment.
NA-Selank Amidate modulates multiple neurotransmitter systems including GABA, dopamine, and serotonin, while regulating brain-derived neurotrophic factor (BDNF). It allosterically modulates GABAA receptors without causing the sedation or dependency of benzodiazepines. The peptide activates serotonin metabolism in the hypothalamus and brainstem, and increases BDNF levels to promote neuronal growth and differentiation.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Acetylated and amidated Selank derivative.
Proposed anxiolytic and cognitive research based on Selank-like neurotransmission; derivative-specific validation is limited.
Not reported for this derivative; cited 14-day studies concern Selank.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
Selank Administration Affects Expression of Genes in GABAergic Neurotransmission
Selank Clinical Trial in Anxiety Disorders
Selank and Serotonin Metabolism
Selank and BDNF Expression
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
